What we do:

Amagma is developing antibody therapies to treat human diseases driven by enzyme hyperactivity.  In many inflammatory conditions, overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses. Using state-of-the-art antibody discovery and optimization strategies, we can selectively target domains of these enzymes and block their activity. Our ability to identify highly specific and differentiated antibodies allows us to overcome the challenges historically associated with this target class.

Management Team

Board of Directors